United States Patent 9,850,229: What Is Claimed in Melanoma BRAF Testing + Oral BRAF-Pathway Agent + MEK Inhibitor
US Drug Patent 9,850,229 claims a treatment method for melanoma that is anchored on (1) detecting a mutant BRAF kinase and (2) orally administering an orally delivered BRAF-pathway agent (specified by a precise chemical name) in combination with a MEK inhibitor. The core claim set is a “BRAF mutant detection → oral administration of specific methyl carbamate compound → add MEK inhibitor” framework, with dependent claims narrowing to B-Raf V600E, metastatic melanoma, route/formulation (capsule), and MEK inhibitor identity including ARRY-438162.
What Is the Claim Scope (Independent Claim 1)?
Independent claim 1
Claim 1 is structured as a two-step method:
- Detecting a mutant BRAF kinase in the melanoma; and
- Orally administering a therapeutically effective amount comprising two administered components:
- (i) a pharmaceutical composition comprising the following active compound (or salt):
- methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
- (ii) a pharmaceutical composition comprising a MEK inhibitor
Key scope levers in claim 1
- Tumor biomarker gating: requires “detecting a mutant BRAF kinase in the melanoma.”
- Route requirement: requires oral administration of the therapeutically effective amount that includes the specified BRAF-pathway compound plus a MEK inhibitor.
- Combination requirement: the method requires the presence of both:
- the specific methyl carbamate compound; and
- a MEK inhibitor (but claim 1 does not yet limit which one).
How Broad Are the “MEK inhibitor” Dependencies?
Claim 5 (and downstream MEK selection)
Claim 5 limits the MEK inhibitor to a defined set of known MEK inhibitors:
- AS703026
- MSC1936369B
- GSK1120212
- AZD6244
- PD-0325901
- ARRY-438162
- RDEA119
- GDC0941
- GDC0973
- TAK-733
- RO5126766
- XL-518
This list is repeated in multiple dependent claims (11, 16, 19), each further narrowed by other features (B-Raf V600E and/or metastatic disease and/or ARRY-438162).
Claim 6 / 12 / 17 / 20
These dependents lock the MEK inhibitor to:
So, the patent is layered:
- Claim 1: any MEK inhibitor (not specified)
- Claim 5: one of 12 named MEK inhibitors
- Claim 6: ARRY-438162 specifically (most commercially relevant)
- Multiple dependent claims then tie ARRY-438162 to B-Raf V600E and/or metastatic melanoma.
What “Method” Variants Are Covered: Non-fixed vs Sequential vs Concurrent?
The patent explicitly manages combination regimen geometry.
Non-fixed combination requirement
- Claim 2: the BRAF-pathway compound composition and the MEK inhibitor composition are administered as a non-fixed combination.
Sequential administration
- Claim 3: the non-fixed components are administered sequentially.
Concurrent administration
- Claim 9: the non-fixed components are administered concurrently.
Practical read-through: the claims cover both concurrent and sequential regimens for separate pharmaceutical compositions (non-fixed combination), each paired with the same biomarker detection premise and oral BRAF-pathway compound component.
What Disease and Biomarker Subsets Are Captured?
B-Raf V600E
Metastatic melanoma
Multiple dependents expand scope to:
- Claim 15: metastatic melanoma (tied to claim 4’s B-Raf V600E premise via the dependency chain)
- Claim 18: metastatic melanoma (tied to claim 10’s B-Raf V600E premise)
- Claims 16, 19: metastatic + biomarker + MEK selection
- Claims 17 and 20: metastatic + biomarker + MEK = ARRY-438162
Net effect: the patent’s strongest coverage concentrates on the clinical apex of melanoma targeted therapy: B-Raf V600E and metastatic disease, with MEK options spanning the listed cohort and a dedicated dependency for ARRY-438162.
What Does the Patent Lock Down on Formulation?
Capsule formulation
- Claim 7: the methyl carbamate composition is formulated as a capsule
- Claim 8: repeats capsule limitation in the ARRY-438162 branch
- Claim 13 and 14: repeat capsule limitation further down the dependency chain
Scope impact: capsule formulation limitations apply only to those dependent claims; they do not narrow claim 1 unless asserted through those dependents.
Claim Set Map (Dependency and Scope Interactions)
| Claim |
Added limitation(s) beyond prior claim |
| 1 |
Method: detect mutant BRAF kinase; orally administer methyl carbamate (specified) + MEK inhibitor |
| 2 |
Administer components as non-fixed combination |
| 3 |
Administer components sequentially |
| 4 |
Melanoma = B-Raf V600E |
| 5 |
MEK inhibitor is one of 12 named agents (includes ARRY-438162) |
| 6 |
MEK inhibitor = ARRY-438162 |
| 7 |
BRAF-pathway compound formulated as capsule |
| 8 |
Capsule + ARRY-438162 branch |
| 9 |
Administer components concurrently |
| 10 |
Melanoma = B-Raf V600E (in concurrent branch) |
| 11 |
MEK inhibitor limited to 12 named agents (in concurrent + V600E branch) |
| 12 |
MEK inhibitor = ARRY-438162 (in concurrent + V600E branch) |
| 13 |
Capsule limitation in V600E + ARRY-438162 chain |
| 14 |
Capsule limitation in V600E + ARRY-438162 chain |
| 15 |
Melanoma = metastatic melanoma |
| 16 |
Metastatic + V600E + MEK list |
| 17 |
Metastatic + V600E + MEK = ARRY-438162 |
| 18 |
Metastatic melanoma (in concurrent + V600E branch) |
| 19 |
Metastatic + V600E + MEK list (concurrent) |
| 20 |
Metastatic + V600E + MEK = ARRY-438162 (concurrent) |
Coverage take: the patent provides multiple claim “entry points” into combination therapy practice depending on the regimen geometry (non-fixed, sequential, concurrent) and the biomarker/disease state (V600E, metastatic) and specific MEK inhibitor.
How to Treat This as a Patent Landscape Asset (Strategic Scope View)
1) The claim is a biomarker-triggered combination method
Any infringing use must follow:
- melanoma patient selection based on detected mutant BRAF kinase, plus
- oral dosing of the specified methyl carbamate compound, plus
- MEK inhibition (varies by asserted dependent claim).
This is not merely a pharmaceutical composition claim. It is a use method anchored in diagnostics + dosing.
2) It is built to capture real-world combination regimens
The inclusion of:
- non-fixed combination,
- sequential administration, and
- concurrent administration
maps to how most combination regimens are operationalized (separate products, flexible schedules).
3) The claim’s MEK inhibitor list is broad
The 12-member set includes many MEK inhibitors that entered melanoma therapy or preclinical/clinical progression. If enforcement targets named competitors, claim 5 provides a clean list boundary for “covered MEK inhibitors” versus “unlisted MEK inhibitors.”
4) ARRY-438162 gets a dedicated spotlight
Multiple dependents specify ARRY-438162, and those dependents also layer on:
- B-Raf V600E
- metastatic melanoma
- sequential and concurrent forms
- capsule formulation for the BRAF-pathway agent
That makes ARRY-438162 a key focal point for any freedom-to-operate assessment against this patent’s dependent claims.
Patent Landscape: What Competing Drug Classes Does This Claim Intersect?
The patent’s practical intersection points are:
- BRAF-mutant melanoma treatment paradigm
- Oral targeted BRAF-pathway small molecule (specified by name in claim 1)
- MEK inhibition layer
- Diagnostic-linked treatment selection (“detecting mutant BRAF kinase”)
Competitor pressure points inferred from the claim language
Even without mapping the full prosecution history, the claim language itself implies the likely crowded landscape areas:
- MEK inhibitors in the listed set are all inside the MEK scope for at least claim 5/11/16/19 (and the ARRY-438162 dependents)
- BRAF-pathway compound swaps are likely outside the claim unless they fall inside the specific methyl carbamate definition (claim 1 is compound-specific)
Actionable Claim-Landscape Implications for R&D and Investment Screening
If you plan to develop or commercialize a competing regimen
The patent’s infringement risk concentrates on combinations that match all of:
- BRAF mutant detection in melanoma (V600E triggers dependent scope)
- Oral administration of the specified methyl carbamate compound
- MEK inhibitor co-administration where the MEK inhibitor is one of the listed agents (for the narrower dependents) or any MEK inhibitor (for claim 1, as written)
- Regimen geometry (non-fixed, sequential or concurrent) for dependents 2-3 and 9-13/14 and for metastatic/V600E dependents
If you plan to design around
Design-around paths must break at least one claim element:
- remove the specific methyl carbamate component,
- avoid co-administering a MEK inhibitor covered in the relevant asserted dependent claim,
- avoid the claimed regimen format and/or avoid the diagnostic-linked selection requirement,
- or move outside the biomarker/disease state (for dependents) such as V600E and metastatic melanoma.
(Those are claim-element levers created by the text; enforcement realities depend on claim interpretation and evidence of use.)
Key Takeaways
- US 9,850,229 is a diagnostic-triggered, oral combination method: detect mutant BRAF kinase in melanoma and orally administer the specified methyl carbamate plus a MEK inhibitor.
- The claim set covers non-fixed combination dosing in both sequential (claim 3) and concurrent (claim 9) formats.
- Dependent claims narrow the biomarker to B-Raf V600E and the disease subset to metastatic melanoma, then narrow MEK to a 12-agent list and separately spotlight ARRY-438162.
- Capsule formulation of the methyl carbamate appears in multiple dependents (claims 7, 8, 13, 14).
- For landscape screening, the highest-risk zone is BRAF V600E metastatic melanoma treated with the specified oral BRAF-pathway compound plus ARRY-438162 or other MEK inhibitors from the enumerated list.
FAQs
1) Does claim 1 require B-Raf V600E specifically?
No. Claim 1 requires only detection of a mutant BRAF kinase. B-Raf V600E is added in dependent claim 4 and subsequent branches.
2) Does the patent require a fixed-dose combination product?
No. It requires a non-fixed combination in claim 2 and the regimen dependents, meaning the components can be separate compositions.
3) Are sequential and concurrent regimens both covered?
Yes. Sequential administration is claimed in claim 3, and concurrent administration is claimed in claim 9.
4) Which MEK inhibitors are explicitly enumerated in the dependent claims?
Claim 5 lists AS703026, MSC1936369B, GSK1120212, AZD6244, PD-0325901, ARRY-438162, RDEA119, GDC0941, GDC0973, TAK-733, RO5126766, and XL-518. Dependent claims then narrow further, including a dedicated ARRY-438162 branch.
5) Is capsule formulation required for all coverage?
No. Capsule formulation is limited to dependent claims (not claim 1).
References
[1] United States Patent No. 9,850,229 (claim set provided by user).
